Research article Special Issues

Brain proteomics links oxidative stress with metabolic and cellular stress response proteins in behavioural alteration of Alzheimer’s disease model rats

  • Received: 29 August 2019 Accepted: 28 October 2019 Published: 15 November 2019
  • Alzheimer’s disease (AD) impairs memory and learning related behavioural performances of the affected person. Compared with the controls, memory and learning related behavioural performances of the AD model rats followed by hippocampal proteomics had been observed in the present study. In the eight armed radial maze, altered performance of the AD rats had been observed. Using liquid chromatography coupled tandem mass spectrometry (LC-MS/MS), 822 proteins had been identified with protein threshold at 95.0%, minimum peptide of 2 and peptide threshold at 0.1% FDR. Among them, 329 proteins were differentially expressed with statistical significance (P < 0.05). Among the significantly regulated (P < 0.05) 329 proteins, 289 met the criteria of fold change (LogFC of 1.5) cut off value. Number of proteins linked with AD, oxidative stress (OS) and hypercholesterolemia was 59, 20 and 12, respectively. Number of commonly expressed proteins was 361. The highest amount of proteins differentially expressed in the AD rats were those involved in metabolic processes followed by those linked with OS. Most notable was the perturbed state of the cholesterol metabolizing proteins in the AD group. Current findings suggest that proteins associated with oxidative stress, glucose and cholesterol metabolism and cellular stress response are among the mostly affected proteins in AD subjects. Thus, novel therapeutic approaches targeting these proteins could be strategized to withstand the ever increasing global AD burden.

    Citation: Mohammad Azizur Rahman, Shahdat Hossain, Noorlidah Abdullah, Norhaniza Aminudin. Brain proteomics links oxidative stress with metabolic and cellular stress response proteins in behavioural alteration of Alzheimer’s disease model rats[J]. AIMS Neuroscience, 2019, 6(4): 299-315. doi: 10.3934/Neuroscience.2019.4.299

    Related Papers:

    [1] Adil Yousif, Awad Ali . The impact of intervention strategies and prevention measurements for controlling COVID-19 outbreak in Saudi Arabia. Mathematical Biosciences and Engineering, 2020, 17(6): 8123-8137. doi: 10.3934/mbe.2020412
    [2] Tao Chen, Zhiming Li, Ge Zhang . Analysis of a COVID-19 model with media coverage and limited resources. Mathematical Biosciences and Engineering, 2024, 21(4): 5283-5307. doi: 10.3934/mbe.2024233
    [3] Salma M. Al-Tuwairqi, Sara K. Al-Harbi . Modeling the effect of random diagnoses on the spread of COVID-19 in Saudi Arabia. Mathematical Biosciences and Engineering, 2022, 19(10): 9792-9824. doi: 10.3934/mbe.2022456
    [4] Lin Feng, Ziren Chen, Harold A. Lay Jr., Khaled Furati, Abdul Khaliq . Data driven time-varying SEIR-LSTM/GRU algorithms to track the spread of COVID-19. Mathematical Biosciences and Engineering, 2022, 19(9): 8935-8962. doi: 10.3934/mbe.2022415
    [5] Sarah R. Al-Dawsari, Khalaf S. Sultan . Modeling of daily confirmed Saudi COVID-19 cases using inverted exponential regression. Mathematical Biosciences and Engineering, 2021, 18(3): 2303-2330. doi: 10.3934/mbe.2021117
    [6] Weike Zhou, Aili Wang, Fan Xia, Yanni Xiao, Sanyi Tang . Effects of media reporting on mitigating spread of COVID-19 in the early phase of the outbreak. Mathematical Biosciences and Engineering, 2020, 17(3): 2693-2707. doi: 10.3934/mbe.2020147
    [7] Sarafa A. Iyaniwura, Musa Rabiu, Jummy F. David, Jude D. Kong . Assessing the impact of adherence to Non-pharmaceutical interventions and indirect transmission on the dynamics of COVID-19: a mathematical modelling study. Mathematical Biosciences and Engineering, 2021, 18(6): 8905-8932. doi: 10.3934/mbe.2021439
    [8] Yue Deng, Siming Xing, Meixia Zhu, Jinzhi Lei . Impact of insufficient detection in COVID-19 outbreaks. Mathematical Biosciences and Engineering, 2021, 18(6): 9727-9742. doi: 10.3934/mbe.2021476
    [9] Damilola Olabode, Jordan Culp, Allison Fisher, Angela Tower, Dylan Hull-Nye, Xueying Wang . Deterministic and stochastic models for the epidemic dynamics of COVID-19 in Wuhan, China. Mathematical Biosciences and Engineering, 2021, 18(1): 950-967. doi: 10.3934/mbe.2021050
    [10] Saima Akter, Zhen Jin . A fractional order model of the COVID-19 outbreak in Bangladesh. Mathematical Biosciences and Engineering, 2023, 20(2): 2544-2565. doi: 10.3934/mbe.2023119
  • Alzheimer’s disease (AD) impairs memory and learning related behavioural performances of the affected person. Compared with the controls, memory and learning related behavioural performances of the AD model rats followed by hippocampal proteomics had been observed in the present study. In the eight armed radial maze, altered performance of the AD rats had been observed. Using liquid chromatography coupled tandem mass spectrometry (LC-MS/MS), 822 proteins had been identified with protein threshold at 95.0%, minimum peptide of 2 and peptide threshold at 0.1% FDR. Among them, 329 proteins were differentially expressed with statistical significance (P < 0.05). Among the significantly regulated (P < 0.05) 329 proteins, 289 met the criteria of fold change (LogFC of 1.5) cut off value. Number of proteins linked with AD, oxidative stress (OS) and hypercholesterolemia was 59, 20 and 12, respectively. Number of commonly expressed proteins was 361. The highest amount of proteins differentially expressed in the AD rats were those involved in metabolic processes followed by those linked with OS. Most notable was the perturbed state of the cholesterol metabolizing proteins in the AD group. Current findings suggest that proteins associated with oxidative stress, glucose and cholesterol metabolism and cellular stress response are among the mostly affected proteins in AD subjects. Thus, novel therapeutic approaches targeting these proteins could be strategized to withstand the ever increasing global AD burden.


    One of the most global deathly diseases is HIV (Human Immunodeficiency Virus), which has its genesis from crossed kinds from chimpanzees to humans. No one knew this disease before 1980, and its transmission was not coupled with visible signs or symptoms. Almost, by 1980, HIV has spread to the five continents, also within this interval of time, more than 300,000 persons were infected by HIV. Another well-known deathly infectious disease is called Ebola. It killed many people around the world in the past years. Some scientists believed that its transmission comes from an infected animal such as non-human mammals or bats. Many other deathly diseases are existing due to the interaction between different living beings and humans. So far, humans have developed several medical protocols and techniques to protect themselves [1].

    Now, all the world suffering from the COVID-19 outbreak, which is currently continuing, and the number of infections is rising steadily. This is due to the presence of many factors that increase the complexities of COVID-19 infection and create barriers to disease management. Among the most important of these barriers is the origin of the infection is still unknown, and the incubation period of the virus is entirely unlimited. Moreover, there is yet no direct treatment for this virus, or anti-vaccine. Therefore, disease control largely depends on timely diagnosis and isolation. One essential factor in the spread of this disease is the transition of infected people from one place to another, which affects more people and therefore causes the spread of this disease. As a result, many countries have prohibited air traffic for a long time, and they stopped all kinds of sports and competitions. Besides, every country around the globe is trying to reduce unnecessary travel and to reduce cases of infection in their countries [2].

    Thus, scientists and researchers all over the world are trying to find out and improve vaccine or cure for the outbreak. So that in the future, such as pandemic may be controlled, from a medical engineering point framework, an infectious disease can be well known and understood by using the mathematical models. This idea was started in 1927. After that, many different mathematical models have been constructed for various diseases and infections [3,4,5,6,7,8]. Wu et al. [9] introduced the well-known SEIR model (Susceptible-Exposed-Infectious-Recovered) model to describe the transmission dynamics and estimated the national and global spread of the disease, depending on reported data from December 31, 2019, to January 28, 2020. They also estimated that the basic reproductive number for COVID-19 was about 2.68. Read et al. [10] reported a value of 3.1 for the basic reproductive number based on data fitting of the SEIR model, using an assumption of Poisson-distributed daily time increments. Tang et al. [11] proposed a deterministic compartmental model incorporating the clinical progression of the disease, the individual epidemiological status, and the involvement measures. They found that the reproductive control number could be as high as 6.47, and that involvement strategies such as condensed contact tracing followed by isolation and quarantine can effectively reduce the control reproduction number and the transmission risk. Imai et al. [12] conducted computational modeling of potential epidemic tracks to estimate the size of the disease outbreak in Wuhan, with a focus on the human to other human transmissions. Their results imply that control measures need to block well over 60% of transmission to be effective in containing the outbreak. Also, Gao et al. [13] developed a deep learning algorithm to analyze the infectivity of the novel coronavirus and predict its potential hosts. Their results indicate that bats and minks maybe two animal hosts of this virus. Most of these models have emphasized the significant role of the direct, human-to-human transmission pathway in this epidemic, as highlighted by the facts that the majority of the infected individuals did not have any contact with the marketplaces in Wuhan, that the number of infections has been rapidly increasing, and that the disease has spread to all provinces in China as well as more than 20 other countries. Many infected individuals exhibit a relatively long incubation period so that they do not show any symptoms and are unaware of their infection for as long as 10–14 days. During this time, they can easily transmit the disease to other people through direct contact. On the other hand, the models published thus far have not considered the role of the environment in the transmission of COVID-19. Several other modeling studies have already been performed for the COVID-19 epidemic [9,10,14,15,16,17,18,19,20,21,22,23].

    Because the mathematical model can reach understood and definite conclusions about the COVID's outbreak, a cascade of SEIR models has been constructed and developed to describe the mechanisms of its transmission from the source of infection, reservoir, hosts to humans [22]. De la Sen, M., et al. discussed a generalized time-varying SEIR propagation disease model subject to delays which potentially involves mixed regular and impulsive vaccination rules [24]. Song et al. studied the SVEIRS infectious disease model with pulse and two-time delays. The pulse vaccination strategy is used as an effective strategy for the elimination of infectious disease [25].

    Using a modified version of similar models, this paper is devoted to predicting the new COVID-19 model to be more suitable for more cases in any country by mathematical analysis of the considered model. Within this work, a proposed SEIR model has been constructed with global analysis. We aim to discover the dynamics of the transmission of the virus through humans. Another target is to study and find out the ideal protocols, control, and strategies that can reduce the outbreak significantly based on data on spreading the COVID-19 in Saudi Arabia.

    During spreading COVID-19 in any country, the population could be divided into four dynamic sub-populations (see figure 1) which are described with the parameters of transmission rates as follows [1,7,17,24,26]:

    Figure 1.  The flowchart of the proposed SEIR model.

    ●   $S\left( t \right)$ is devoted to the susceptible population who are healthy but can contract the disease.

    ●   $E\left( t \right)$ is dedicated to the exposed population who infected but not yet infectious.

    ●   $I\left( t \right)$ is dedicated to the people who confirmed infected and under treatment.

    ●   $R\left( t \right)$ is defined as the individuals who have recovered and cannot contract the COVID-19 again.

    ●   $\alpha \geqslant 0$ is defined as the transmission rate from a susceptible population to infected.

    ●   $\Lambda > 0$ comprises of new birth and new residents per unit value of time

    ●   ${d_1} \geqslant 0$ is the natural death rate.

    ●   ${d_2} \geqslant 0$ is the death rate due to COVID-19.

    ●   ${\sigma _1} \geqslant 0$ is the transmission rate of recovery from the population who confirmed infected.

    ●   ${\sigma _2} \geqslant 0$ is the transmission rate of recovery from the exposed population.

    ●   $r \geqslant 0$ is the transmission rate of confirmed infected from the exposed population.

    We define the total population size by $N\left( t \right)$ as follows [1,7,26]:

    $N\left( t \right) = S\left( t \right) + E\left( t \right) + I\left( t \right) + R\left( t \right)$ (1)

    According to the inflows and outflows in Figure 1, we can convert them into first-order ordinary non-linear differential equations as follows [1,7,26]:

    $ \frac{{dS\left( t \right)}}{{dt}} = \Lambda - \alpha S\left( t \right)E\left( t \right) - {d_1}S\left( t \right) $ (2)
    $\frac{{dE\left( t \right)}}{{dt}} = \alpha S\left( t \right)E\left( t \right) - \left( {{d_1} + {\sigma _2} + r} \right)E\left( t \right)$ (3)
    $\frac{{dI\left( t \right)}}{{dt}} = rE\left( t \right) - \left( {{d_1} + {d_2} + {\sigma _1}} \right)I\left( t \right) $ (4)
    $\frac{{dR\left( t \right)}}{{dt}} = {\sigma _1}I\left( t \right) + {\sigma _2}E\left( t \right) - {d_1}R\left( t \right)$ (5)

    By simplify the above equations, we have

    $\frac{{dS\left( t \right)}}{{dt}} = \Lambda - \left( {\alpha E\left( t \right) + {d_1}} \right)S\left( t \right)$ (6)
    $\frac{{dE\left( t \right)}}{{dt}} = \alpha S\left( t \right)E\left( t \right) - {\varepsilon _1}E\left( t \right)$ (7)
    $\frac{{dI\left( t \right)}}{{dt}} = rE\left( t \right) - {\varepsilon _2}I\left( t \right)$ (8)
    $\frac{{dR\left( t \right)}}{{dt}} = {\sigma _1}I\left( t \right) + {\sigma _2}E\left( t \right) - {d_1}R\left( t \right)$ (9)

    where ${\varepsilon _1} = \left( {{d_1} + {\sigma _2} + r} \right)$ and ${\varepsilon _2} = \left( {{d_1} + {d_2} + {\sigma _1}} \right)$.

    All the solutions of the proposed SEIR model with its initial condition is a subset in the interval $[0, \infty )$ and $\left\{ {S\left( t \right), E\left( t \right), I\left( t \right), R\left( t \right)} \right\} \geqslant 0$ for all values $0 \leqslant t < \infty $.

    Proof. All the right-hand sides of the proposed SEIR model is completely continuous and locally Lipschitzian on $ \mathbb{R} $. The solutions $\left\{ {S\left( t \right), E\left( t \right), I\left( t \right), R\left( t \right)} \right\}$ with its initial conditions exist and are unique in the interval $\left. {\left[ {0, \infty } \right.} \right)$ [7].

    From the Eq (6) where $\left( {\alpha E\left( t \right) + {d_1}} \right) = M \geqslant 0$ and $\Lambda > 0$, then, we obtain the following valid inequality

    $\frac{{dS\left( t \right)}}{{dt}} \geqslant - M\, S\left( t \right)$ (10)

    By solving the above differential inequality, we get

    $S\left( t \right) \geqslant S\left( 0 \right){e^{ - M\, t}} \geqslant 0$ (11)

    Hence, $S\left( t \right)$ is a non-negative function for all values $t \in \left[ {0, \infty } \right)$.

    From the Eq (7), we have

    $\frac{{dE\left( t \right)}}{{dt}} \geqslant - {\varepsilon _1}E\left( t \right)$ (12)

    which gives

    $E\left( t \right) \geqslant E\left( 0 \right){e^{ - {\varepsilon _1}t}} \geqslant 0$ (13)

    Hence, $E\left( t \right)$ is a non-negative function for all values $t \in \left[ {0, \infty } \right)$.

    In similar manners for the rest equations, we have

    $\frac{{dI\left( t \right)}}{{dt}} \geqslant - {\varepsilon _2}I\left( t \right) \to I\left( t \right) \geqslant I\left( 0 \right){e^{ - {\varepsilon _2}t}} \geqslant 0$ (14)

    and

    $\frac{{dR\left( t \right)}}{{dt}} \geqslant - {d_1}R\left( t \right) \to R\left( t \right) \geqslant R\left( 0 \right){e^{ - {d_1}t}} \geqslant 0$ (15)

    Hence, $I\left( t \right){\rm{and}}\, R\left( t \right)\, $ are non-negative functions for all values of $t \in \left[ {0, \infty } \right)$ which complete the proof.

    All the solutions of the proposed SEIR model structure that initiate in $ {\mathbb{R}}_{+}^{4} $ are bounded inside the region $ \Omega $ defined by $ \Omega = \left\{\left(S, E, I, R\right)\in {\mathbb{R}}_{+}^{4}:0\le N\left(t\right)\le \frac{\Lambda }{{d}_{1}}\right\} $ as $t \to \infty $.

    Proof. By differentiating both sides of the Eq (1), we get

    $N'\left( t \right) = S'\left( t \right) + E'\left( t \right) + I'\left( t \right) + R'\left( t \right)$ (16)

    Substituting from the proposed SEIR model (6)–(9), we get

    $N'\Lambda + {d_1}N = \Lambda - {d_2}I$ (17)

    From theorem 1, we have ${d_2}I\left( t \right) \geqslant 0$; hence, the following inequality is valid

    $N'\left( t \right) + {d_1}N\left( t \right) \leqslant \Lambda $ (18)

    Then, we obtain

    $N\left( t \right) \leqslant \left( {N\left( 0 \right) - \frac{\Lambda }{{{d_1}}}} \right){e^{ - {d_1}t}} + \frac{\Lambda }{{{d_1}}}$ (19)

    Thus, when $t \to \infty $ we get the solution $N\left( t \right) \subset \left[ {0, \frac{\Lambda }{{{d_1}}}} \right]$, which completes the proof.

    To determine the epidemic equilibrium of this model, we set all the derivatives equal to zero and solve the system as follows [7]:

    $S'\left( t \right) = E'\left( t \right) = I'\left( t \right) = R'\left( t \right) = 0$ (20)

    which gives

    $0 = \Lambda - \alpha SE - {d_1}S$ (21)
    $0 = \alpha SE - {\varepsilon _1}E$ (22)
    $0 = rE - {\varepsilon _2}I$ (23)
    $0 = {\sigma _1}I + {\sigma _2}E - {d_1}R$ (24)

    From the Eq (22), we have

    $S = \frac{{{\varepsilon _1}}}{\alpha }$ (25)

    From the Eq (23), we have

    $E = \frac{{{\varepsilon _2}}}{r}I$ (26)

    Substitute from Eqs (25) and (26) into the Eq (21), we get

    $I = \frac{{r{d_1}}}{{\alpha {\varepsilon _2}}}\left( {\frac{{\alpha \, \Lambda }}{{{d_1}{\varepsilon _1}}} - 1} \right) = \frac{{r{d_1}}}{{\alpha {\varepsilon _2}}}\left( {{\Re _0} - 1} \right)$ (27)

    where

    ${\Re _0} = \frac{{\alpha \, \Lambda }}{{{d_1}{\varepsilon _1}}} = \frac{{\alpha \, \Lambda }}{{{d_1}\left( {{d_1} + {\sigma _2} + r} \right)}}$ (28)

    The number ${\Re _0}$ is called the reproduction number (RBN) [1,7].

    The reproduction number is positive, and it is zero if there is no transmission, where $\alpha = 0.0$ and it can be interpreted as the number of secondary cases or the new infection rate.

    Substitute from Eq (27) into Eq (26), we obtain

    $E = \frac{{{d_1}}}{\alpha }\left( {{\Re _0} - 1} \right)$ (29)

    Substitute from Eqs (25), (27), and (29) into Eq (24), we get

    $R = \left( {\frac{{r{\sigma _1} + {\varepsilon _2}{\sigma _2}}}{{\alpha {\varepsilon _2}}}} \right)\left( {{\Re _0} - 1} \right)$ (30)

    Thus, at disease-free equilibrium (DFE) ${\Re _0} = 1$ gives $E = I = R = 0$ and leads to $\frac{{{\varepsilon _1}}}{\alpha } = \frac{\Lambda }{{{d_1}}}$, which agree with Eq (25) and the domain of solution in theorem 2.

    Then, if ${\Re _0} > 1$ the system has a unique endemic equilibrium [7]:

    $E_0^* = \left( {{S^*}, {E^*}, {I^*}, {R^*}} \right)$ (31)

    where ${S^*} = \frac{\Lambda }{{{d_1}}}$, ${E^*} = \frac{{{d_1}}}{\alpha }\left( {{\Re _0} - 1} \right)$, $\, {I^*} = \frac{{r{d_1}}}{{\alpha {\varepsilon _2}}}\left( {{\Re _0} - 1} \right)$, and ${R^*}\, = \left( {\frac{{r{\sigma _1} + {\varepsilon _2}{\sigma _2}}}{{\alpha {\varepsilon _2}}}} \right)\left( {{\Re _0} - 1} \right)$.

    Thus, the system has a unique disease-free equilibrium ${E_0}$ when ${\Re _0} = 1$ and has a unique endemic equilibrium $E_0^*$ when ${\Re _0} > 1$ [7].

    To get the reproduction number ${\Re _0}$ by using the Jacobian matrix method, we consider the disease-free equilibrium (DFE) of the proposed SEIR model is acquired by setting $E = I = R = 0$ in the Eqs (21)–(24), hence, we obtain DFE in the form ${E_0} = \left( {\frac{\Lambda }{{{d_1}}}, 0, 0, 0} \right)$ [1,7].

    The Jacobian matrix of the proposed SEIR model takes the following form:

    ${J_{{E_0}}} = \left[ {αEd1αS00αEαSε1000rε200σ2σ1d1
    } \right]$
    (32)

    By using the Jacobian's linearization method, we will linearize the first two equations considering the equilibrium situation of the system $I = 0, E = 0, \, \, {\rm{and}}\, \, S = \frac{\Lambda }{{{d_1}}}$.

    Hence, we consider the following functions

    $F\left( {S, E} \right) = \Lambda - \alpha S\left( t \right)E\left( t \right) - {d_1}S\left( t \right)$ (33)
    $G\left( {S, E} \right) = \alpha S\left( t \right)E\left( t \right) - {\varepsilon _1}E\left( t \right)$ (34)

    Then, we have

    $\left[ {FSFEGSGE
    } \right]\left[ {S(t)S(0)E(t)E(0)
    } \right] = \left[ {αE(0)d1αS(0)αE(0)αS(0)ε1
    } \right]\left[ {S(t)S(0)E(t)E(0)
    } \right]$
    (35)

    By substituting from the equilibrium position, we obtain

    $\left[ {S(t)E(t)
    } \right] = \left[ {d1αΛd10αΛd1ε1
    } \right]\left[ {S(t)Λd1E(t)
    } \right]$
    (36)

    Hence, the coupled non-linear Eqs (6) and (7) has been linearized to the forms:

    $\frac{{dS\left( t \right)}}{{dt}} = \Lambda - {d_1}S\left( t \right) - \frac{{\alpha \Lambda }}{{{d_1}}}E\left( t \right)$ (37)

    and

    $\frac{{dE\left( t \right)}}{{dt}} = \left( {\frac{{\alpha \Lambda - {d_1}{\varepsilon _1}}}{{{d_1}}}} \right)E\left( t \right)$ (38)

    Hence, the Jacobian matrix of the proposed SEIR model after linearization at equilibrium is given by [1,7]:

    ${J_{{E_0}}} = \left[ {d1αΛd1000αΛd1ε1000rε200σ2σ1d1
    } \right]$
    (39)

    By calculating the characteristic equation given by $\left| {{J_{{E_0}}} - \lambda {I_4}} \right| = 0$, where $\lambda $ is the eigenvalues parameter and ${I_4}$ is the identity matrix of order four, we obtain the eigenvalues of the matrix ${J_{{E_0}}}$ as follows:

    $\left[ {λ1λ2λ3λ4
    } \right] = \left[ {ε2d1d1αΛd1ε1d1
    } \right]$
    (40)

    Hartman–Grobman theorem state that the solutions of a square system of non-linear ordinary differential Eqs (6)–(9) in a neighborhood of a steady-state look "qualitatively" just like the solutions of the linearized system near the point ${E_0} = \left( {\frac{\Lambda }{{{d_1}}}, 0, 0, 0} \right)$. This result holds only when the equilibrium is a hyperbolic equilibrium; that is when none of the eigenvalues of the matrix ${J_{{E_0}}}$ have zero real part [7].

    Thus, from (40) we obtain the following condition of equilibrium

    $\alpha \, \Lambda - {d_1}{\varepsilon _1} \lt 0$ (41)

    Thus, $\frac{{\alpha \Lambda }}{{{d_1}{\varepsilon _1}}} = {\Re _0} < 1$ is the condition of equilibrium.

    If the matrix ${J_{{E_0}}}$ is obtained from the linearization and is the Jacobian evaluated at equilibrium ${\rm{DFE}}\left( {{E_0}} \right) = \left( {\frac{\Lambda }{{{d_1}}}, 0, 0, 0} \right)$, the condition $\left| {{J_{{E_0}}}} \right| \ne 0$ means that the equilibrium is isolated, which means there is a disk around it that does not contain other equilibria.

    Hence, from (39), we have

    $\det \left( {{J_{{E_0}}}} \right) = \det \left[ {d1αΛd1000αΛd1ε1000rε200σ2σ1d1
    } \right] = - {\varepsilon _2}{d_1}\left( {\alpha \, \Lambda - {d_1}{\varepsilon _1}} \right) \ne 0$
    (42)

    Thus, the condition (41) is the only condition of the equilibrium of the proposed SEIR model.

    Therefore, the unique equilibrium condition of the proposed SEIR model is

    $\frac{{\alpha \, \Lambda }}{{{d_1}{\varepsilon _1}}} - 1 \ne 0$ (43)

    and the reproduction number (RBN) ${\Re _0} = \frac{{\alpha \Lambda }}{{{d_1}{\varepsilon _1}}}$ is also unique.

    The proposed SEIR model ${\rm{DFE}}\left( {{E_0}} \right) = \left( {\frac{\Lambda }{{{d_1}}}, 0, 0, 0} \right)$ is locally asymptotically stable under the condition ${\Re _0} < 1$ and unstable when ${\Re _0} > 1$ [7].

    Proof. From the Jacobian matrix of the system (39) which is defined at ${\rm{DFE}}\left( {{E_0}} \right) = \left( {\frac{\Lambda }{{{d_1}}},0,0,0} \right)$ and the eigenvalues (40), we have

    ${\lambda _1} = - {\varepsilon _2} \lt 0, \, \, \, {\lambda _2} = - {d_1} \lt 0, \, \, {\rm{and}}\, {\lambda _3} = - {d_1} \lt 0$ (44)

    Thus, the system is locally stable when ${\lambda _4} = \frac{{\alpha \, \Lambda - {d_1}{\varepsilon _1}}}{{{d_1}}} < 0$, which gives $\frac{{\alpha \, \Lambda }}{{{d_1}{\varepsilon _1}}} < 1$, then, the stability condition takes the form

    ${\Re _0} = \frac{{\alpha \, \Lambda }}{{{d_1}{\varepsilon _1}}} \lt 1$ (45)

    and the instability condition is

    ${\Re _0} = \frac{{\alpha \, \Lambda }}{{{d_1}{\varepsilon _1}}} \gt 1$ (46)

    Thus, we have

    ${\Re _0} \to \left\{ {0>1Unstable situation0=0Notransmission0<1Stable situation
    } \right\}$
    (47)

    Local sensitivity analysis is a sensitivity analysis that examines the change in the output values that result from a change in one input value (one-parameter). The sensitivity or elasticity of the reproduction number ${\Re _0}$ concerning any parameter p is given by [7]:

    $\wp _{{\Re _0}}^p = {{\frac{{\partial {\Re _0}}}{{\partial p}}} \mathord{\left/ {\vphantom {{\frac{{\partial {\Re _0}}}{{\partial p}}} {\frac{{{\Re _0}}}{p}}}} \right. } {\frac{{{\Re _0}}}{p}}} = \pm \frac{{\% \Delta {\Re _0}}}{{\% \Delta p}}$ (48)

    The sensitivity of ${\Re _0}$ concern $p$ is positive if ${\Re _0}$ is increasing concerning p and negative if ${\Re _0}$ is decreasing concerning p.

    Applying the formula (48) into the reproduction number ${\Re _0}$ which takes the form

    ${\Re _0} = \frac{{\alpha \, \Lambda }}{{{d_1}{\varepsilon _1}}} = \frac{{\alpha \, \Lambda }}{{{d_1}\left( {{d_1} + {\sigma _2} + r} \right)}}$ (49)

    Then,

    $\wp _{{\Re _0}}^\alpha = {{\frac{{\partial {\Re _0}}}{{\partial \alpha }}} \mathord{\left/ {\vphantom {{\frac{{\partial {\Re _0}}}{{\partial \alpha }}} {\left( {\frac{{{\Re _0}}}{\alpha }} \right)}}} \right. } {\left( {\frac{{{\Re _0}}}{\alpha }} \right)}} = 1 \gt 0$ (50)
    $\wp _{{\Re _0}}^r = {{\frac{{\partial {\Re _0}}}{{\partial r}}} \mathord{\left/ {\vphantom {{\frac{{\partial {\Re _0}}}{{\partial r}}} {\left( {\frac{{{\Re _0}}}{r}} \right)}}} \right. } {\left( {\frac{{{\Re _0}}}{r}} \right)}} = - \frac{{\, r}}{{{\varepsilon _1}}} \lt 0$ (51)
    $\wp _{{\Re _0}}^{{\sigma _2}} = {{\frac{{\partial {\Re _0}}}{{\partial {\sigma _2}}}} \mathord{\left/ {\vphantom {{\frac{{\partial {\Re _0}}}{{\partial {\sigma _2}}}} {\left( {\frac{{{\Re _0}}}{{{\sigma _2}}}} \right)}}} \right. } {\left( {\frac{{{\Re _0}}}{{{\sigma _2}}}} \right)}} = - \frac{{\, {\sigma _2}}}{{{\varepsilon _1}}} \lt 0$ (52)
    $\wp _{{\Re _0}}^{{d_1}} = {{\frac{{\partial {\Re _0}}}{{\partial {d_1}}}} \mathord{\left/ {\vphantom {{\frac{{\partial {\Re _0}}}{{\partial {d_1}}}} {\left( {\frac{{{\Re _0}}}{{{d_1}}}} \right)}}} \right. } {\left( {\frac{{{\Re _0}}}{{{d_1}}}} \right)}} = - \frac{{\, \left( {{d_1} + {\varepsilon _1}} \right)}}{{{\varepsilon _1}}} \lt 0$ (53)

    The fact that $\wp _{{\Re _0}}^r = - \frac{{\, r}}{{{\varepsilon _1}}}$, $\wp _{{\Re _0}}^{{\sigma _2}} = - \frac{{\, {\sigma _2}}}{{{\varepsilon _1}}}$, and $\wp _{{\Re _0}}^{{d_1}} = - \frac{{\, \left( {{d_1} + {\varepsilon _1}} \right)}}{{{\varepsilon _1}}}$ means that 1% increase in each one of $\left( {r, {\sigma _2}, {d_1}} \right)$ will produce $\left( {\frac{{\, r}}{{{\varepsilon _1}}}, \frac{{\, {\sigma _2}}}{{{\varepsilon _1}}}, \frac{{\, \left( {{d_1} + {\varepsilon _1}} \right)}}{{{\varepsilon _1}}}} \right)\% $ decrease in ${\Re _0}$, respectively.

    From relation (50) $\wp _{{\Re _0}}^\alpha = 1$ means that a 1% increase $\alpha $ will produce a rise of 1% in ${\Re _0}$ [7].

    Lyapunov functions are scalar functions that may be used to prove the global stability of equilibrium. Lyapunov states that if a function $V(x)$ is globally positively definite and radially unbounded, and its time derivative is globally negative, $V(x) < 0\, \, for\, \, all\, \, x \ne {x^*}$ then the equilibrium ${x^*}$ is globally stable for the autonomous system $x' = f\left( x \right)$, and $V\left( x \right)$ is called Lyapunov's function [7].

    The SEIR model ${\rm{DFE}}\left( {{E_0}} \right) = \left( {\frac{\Lambda }{{{d_1}}}, 0, 0, 0} \right)$ is globally stable of the disease-free equilibrium under the condition ${\Re _0} < 1$.

    Proof. We will consider the proposed SEIR model on the space of the first three variables only $\left( {S, E, I} \right)$. It is clear that, if the disease-free equilibrium for the first three equations is globally stable, then $R \to 0$, and the disease-free equilibrium for the full SEIR model is globally stable.

    We construct the Lyapunov function on $ {\mathbb{R}}_{+}^{3} $ in the following form [7]:

    $V = \kappa \left( {S - {S^*} - {S^*}\ln \left( {\frac{S}{{{S^*}}}} \right)} \right) + \frac{E}{{{\varepsilon _1}}} + \frac{I}{r}$ (54)

    where $\kappa $ is a parameter will be determined later, and ${S^*} = \frac{\Lambda }{{{d_1}}}$.

    The Eq (54) shows that, at the disease-free equilibrium $\left( {{S^*} = \frac{\Lambda }{{{d_1}}}, 0, 0} \right)$, $V = 0$.

    Now, we have to show that $V > 0$ for all $\left( {S, E, I} \right) \geqslant \left( {\frac{\Lambda }{{{d_1}}}, 0, 0} \right)$.

    The Eq (54) can be re-written as follows

    $V = \kappa {S^*}\left( {\frac{S}{{{S^*}}} - 1 - \ln \left( {\frac{S}{{{S^*}}}} \right)} \right) + \frac{E}{{{\varepsilon _1}}} + \frac{I}{r}$ (55)

    The first term is positive for any value of $S/{S^*}$, and the rest two terms are also non-negative, so $V > 0$

    Now, we take the derivative of the Eq (54), we obtain

    $V' = \kappa \left( {1 - \frac{{{S^*}}}{S}} \right)S' + \frac{{E'}}{{{\varepsilon _1}}} + \frac{{I'}}{r}$ (56)

    Substitute from the first three equation of the SEIR model and using the Eq (26), we obtain

    $V' = 2\Lambda \kappa - \frac{{\kappa \alpha {\varepsilon _2}}}{r}SI - {d_1}\kappa S - \frac{{{\Lambda ^2}\kappa }}{{S{d_1}}} + \frac{{\kappa \alpha \Lambda {\varepsilon _2}}}{{{d_1}r}}I + \frac{{\alpha {\varepsilon _2}}}{{{\varepsilon _1}r}}SI - \frac{{{\varepsilon _2}}}{r}I$ (57)

    We choose $\kappa = \frac{1}{{{\varepsilon _1}}}$, then we have

    $V' = - \frac{\Lambda }{{{\varepsilon _1}}}\left( {\frac{{{d_1}S}}{\Lambda } + \frac{\Lambda }{{{d_1}S}} - 2} \right) + \frac{{{\varepsilon _2}}}{r}I\left( {{\Re _0} - 1} \right)$ (58)

    Since ${\Re _0} < 1$ then, the last term is non-positive.

    For the first term, consider $\frac{{{d_1}S}}{\Lambda } = x$, then the term inside the brackets takes the form $\left( {x + \frac{1}{x} - 2} \right) = \frac{{{{\left( {x - 1} \right)}^2}}}{x} > 0$, which gives two possibilities. The first one is at the equilibrium point $S = {S^*} = \frac{\Lambda }{{{d_1}}}$, which leads to $x = 1$. Then, the first term completely vanishes. Hence, we have the last term only, and it is non-negative. Thus, $V' < 0$.

    The second possibility is $x \ne 1$, then, the two terms are non-positive. Thus $V' < 0$.

    Therefore, $V' < 0$ for every $\left( {S\left( t \right), E\left( t \right), I\left( t \right)} \right)\, \, \geqslant \left( {\frac{\Lambda }{{{d_1}}}, 0, 0} \right)$.

    According to Lyapunov's theorem, the disease-free equilibrium is globally asymptotically stable for the system of the proposed SEIR model in all [7].

    After linearization of the system of the SEIR model with the initial values, the system takes the form

    $\frac{{dS\left( t \right)}}{{dt}} = \Lambda - {d_1}S\left( t \right) - \frac{{\alpha \Lambda }}{{{d_1}}}E\left( t \right)$ (59)
    $\frac{{dE\left( t \right)}}{{dt}} = \left( {\frac{{\alpha \Lambda - {d_1}{\varepsilon _1}}}{{{d_1}}}} \right)E\left( t \right)$ (60)
    $\frac{{dI\left( t \right)}}{{dt}} = rE\left( t \right) - {\varepsilon _2}I\left( t \right)$ (61)
    $\frac{{dR\left( t \right)}}{{dt}} = {\sigma _1}I\left( t \right) + {\sigma _2}E\left( t \right) - {d_1}R\left( t \right)$ (62)

    We assume the initial conditions of the above system take the form

    ${\left. {\left\{ {S\left( t \right), E\left( t \right), I\left( t \right), R\left( t \right)} \right\}} \right|_{t = 0}} = \left\{ {S\left( 0 \right), E\left( 0 \right), I\left( 0 \right), R\left( 0 \right)} \right\}$ (63)

    To solve the above system, we start to solve the equation (60) as following

    $E\left( t \right) = E\left( 0 \right){\operatorname{e} ^{{\gamma _1}t}}$ (64)

    where ${\gamma _1} = \frac{{\alpha \Lambda - {d_1}{\varepsilon _1}}}{{{d_1}}} $.

    Then, by substitute from Eq (64) into the Eq (61), we get

    $\frac{{dI\left( t \right)}}{{dt}} + {\varepsilon _2}I\left( t \right) = rE\left( 0 \right){\operatorname{e} ^{{\gamma _1}t}}$ (65)

    By solving the above equation, we get the infection function in the form

    $I\left( t \right) = \left( {I\left( 0 \right) - {\gamma _2}} \right){e^{ - {\varepsilon _2}t}} + {\gamma _2}{e^{{\gamma _1}t}}$ (66)

    where $ {\gamma _2} = \frac{{rE\left( 0 \right)}}{{{\gamma _1} + {\varepsilon _2}}} $.

    We can solve the first equation of the system by using the Eq (64)

    $\frac{{dS\left( t \right)}}{{dt}} - {d_1}S\left( t \right) = \Lambda - \frac{{\alpha \Lambda E\left( 0 \right)}}{{{d_1}}}{\operatorname{e} ^{{\gamma _1}t}}$ (67)

    After solving the Eq (67), we get

    $S\left( t \right) = \left( {S\left( 0 \right) + {\gamma _3} - \frac{\Lambda }{{{d_1}}}} \right){e^{ - {d_1}t}} + \left( {\frac{\Lambda }{{{d_1}}} - {\gamma _3}{\operatorname{e} ^{{\gamma _1}t}}} \right)$ (68)

    where $ {\gamma _3} = \frac{\Lambda }{{{d_1}}}\left( {\frac{{\alpha E\left( 0 \right)}}{{{d_1} + {\gamma _1}}} - 1} \right) $.

    By inserting the Eqs (64), (66), and (68) into the Eq (62), we can solve the ordinary differential equation $R\left( t \right)$.

    To verify the proposed SEIR model, we will use the real data of spreading COVID-19 in Saudi Arabia. The spreading of COVID-19 has been stared in Saudi Arabia on March 3, 2020. The discovered cases continued with small numbers until the beginning of April, then the number of cases detected in infection increased. So, we decided to consider April 1, 2020, which is the real beginning of the spread of the COVID-19 epidemic in Saudi Arabia.

    We used the statistics tables which issued from the Saudi Ministry of Health [27]and the daily official statement issued by the ministry as well as from the Wikipedia website [28], which also depends on the ministry's website and some other sites that would announce these statistics.

    Another source of these data is the Saudi Center for Diseases Prevention and Control [29]. To obtain some information about the kingdom's population, mortality rate, and population growth rate, the official website of the General Statistics Authority of Saudi Arabia has been used.

    To study the situation of spreading COVID-19 in Saudi Arabia until June 15, 2020, we will represent the curve of the daily number of infections and the time series curve of the total number of infections as in the Figures 2 and 3.

    Figure 2.  The daily number of infections in Saudi Arabia between 4/1/2020 and 6/15/2020.
    Figure 3.  The total number of infections in KSA between 4/1/2020 and 6/15/2020.

    Figure 2 shows that the number of cases on April 1, 2020, was 157 infections, and it reaches 4507 infections on June 15, 2020, and between the two numbers, the curves passed through many variations up and down. Figure 3 shows that the total number of cases at the same interval started with 157 infections and reaches an accumulated amount of 132,098 infections on June 15, 2020. So, we will use this data through the proposed SEIR model to stand on whether there is a convergence between the model results and the real data [27,28,29].

    According to the official data of Saudi Arabia, we have the following initial data, which is considered as the initial conditions of the system based on the SEIR model, as in Table 1 [27,28,29]:

    Table 1.  The initial conditions of the model SEIR.
    $S\left( 0 \right)$ $E\left( 0 \right)$ Assumed $I\left( 0 \right)$ $R\left( 0 \right)$
    34,218,169 $1.5 \times {10^4}$ 157 99

     | Show Table
    DownLoad: CSV

    where $S\left( 0 \right) = 34,218,169$ is the total population in Saudi Arabia up-to June 15, 2020. The total number of the exposed population infected but not detected by testing has been assumed $E\left( 0 \right) = 1.5 \times {10^4}$, while the number of infections $I\left( 0 \right) = 157$. The recovery number of the population at the same time was $R\left( 0 \right) = 99$.

    The total number of a new birth of Saudi children and new residents $\Lambda \approx 2300\, {\rm{person}}/{\rm{day}}$ and the rate of natural death is around 1030 persons/day which gives ${d_1} \approx 3 \times {10^{ - 5}}$. Some of the other parameters have been calculated or estimated or assumed, as in Table 2.

    Table 2.  The values of parameters in SEIR [1,7,26,27,28,29].
    Parameter Value Background
    $\Lambda $ 2300 Calculated
    ${\sigma _1}$ $0.0024$ Calculated
    ${\sigma _2}$ $2.0 \times {10^{ - 3}}$ Estimated
    $r$ $0.003$ Calculated
    ${d_1}$ $3.0 \times {10^{ - 5}}$ Calculated
    ${d_2}$ $2.7 \times {10^{ - 5}}$ Calculated

     | Show Table
    DownLoad: CSV

    After using the above values of the parameter and by using MAPLE software, we get the results that indicate the number of daily infections as outcomes of the proposed SEIR model. The following figure shows the numerical results of the proposed SEIR model against the real data with different values of the parameter $\alpha $ and RBN $\left( {{\Re _0}} \right)$ to stand on the convergence between them as in Figure 4. It is noted that an increase in the parameter $\alpha $ leads to a rise in the number of infections and RBN $\left( {{\Re _0}} \right)$. The value of the parameter $\alpha $ (the rate of transmission from susceptible population to infected in Saudi Arabia) within the mentioned interval above is $\alpha = \left( {1.0 - 3.0} \right) \times {10^{ - 9}}$.

    Figure 4.  The number of daily infections based on proposed SEIR model with various values of $\alpha \, {\rm{and}}\, {\Re _0}$ parameters against the real data in KSA between 4/1/2020 and 6/15/2020.

    Moreover, the reproduction number RBN $\left( {{\Re _0}} \right)$ is ${\Re _0} = \left( {0.551 - 1.563} \right) \leqslant 1$. This range gives the transmission rate at which the susceptible individual converted to an exposed individual, which means the spreading of the COVID-19 is a critical situation.

    To illustrate the convergence between the results of the proposed SEIR model and the real results, we will display Figure 5, which shows the cumulatively infected numbers within the same interval referred to earlier. It is noted that the curve of the real data is setting between the three cases of the proposed SEIR model with the mention values of $\alpha \, {\rm{and}}\, {\Re _0}$ parameters. It is pointed out that the results of the proposed SEIR model are very closed to the real results, which confirm that this model is maybe more successful than other models.

    Figure 5.  The number of total infections based on the SEIR model with various values of $\alpha \, {\rm{and}}\, {\Re _0}$ parameters against the real data in KSA between 4/1/2020 and 6/15/2020.

    Now, we will predict the situation of spreading COVID-19 in Saudi Arabia based on the current data and parameters with the same rates without any change in the procedures. We illustrate the results of the total number of infections by applying the proposed SEIR model for the next four hundred days, starting from April 1, 2020, and end on May 5, 2021. In Figure 6, the curves and results show whether the number of infections will not breakdown, and the spreading of the COVID-19 will continue with an unstable situation or not. The curves have been done by using the same three values of the parameters $\alpha $. The figure shows that the spreading of COVID-19 will continue with unstable spread without any breakdown, and the number of infections will increase.

    Figure 6.  The number of daily infections based on the SEIR model with various values of $\alpha \, {\rm{and}}\, {\Re _0}$ parameters in KSA for 400 days between 4/1/2020 and 5/5/2021.

    We will show what we should do against this situation in the section of the best protocol to breakdown spreading the COVID-19.

    To study the sensitivity of the critical parameters against the reproduction number RBN $\left( {{\Re _0}} \right)$, we use the Eqs (50)–(53)and represent Figures 79, which show the increment of the value of RBN $\left( {{\Re _0}} \right)$ concerning the parameters $\alpha , {\sigma _2}, \, \, {\rm{and}}\, \, r$. Figure 7 shows the parameter $\alpha $ has a significant effect on the value of the reproduction number ${\Re _0}$, where an increase of the parameter $\alpha $ leads to an increase in the value of the reproduction number ${\Re _0}$. The Saudi Arabia data indicates that for a stable epidemic spreading of COVID-19 ${\Re _0} < 1$, the value of the parameter $\alpha $ must be smaller than the value $1.8 \times {10^{ - 9}}$, which is near to the current situation. Moreover, the Figures 8 and 9 show that the values of all the other studied parameters have significant effects on the increment of the reproduction number ${\Re _0}$. The value of each parameter which gives stable reproduction number $\left( {{\Re _0} < 1} \right)$ individually, when the other parameters are constants, is provided as follows,

    $\alpha \leqslant 1.8 \times {10^{ - 9}}, \, \, {\sigma _2} \geqslant 0.004, \, \, \, r \geqslant 0.005$ (69)
    Figure 7.  The reproduction number against the parameter $\alpha $ $\left( {\alpha \leqslant 1.8 \times {{10}^{ - 9}} \to {\Re _0} \leqslant 1} \right)$.
    Figure 8.  The reproduction number against the parameter ${\sigma _2}$ $\left( {{\sigma _2} \geqslant 0.004 \to {\Re _0} \leqslant 1} \right)$.
    Figure 9.  The reproduction number against the parameter $r$ $\left( {r \geqslant 0.005 \to {\Re _0} \leqslant 1} \right)$.

    Now, we are in the most critical section, which tells us what we should do to breakdown the spreading of COVID-19 in Saudi Arabia. Therefore, in this section, we will study the change of each parameter for the next 400 days of spreading the virus to know which one and which value will make the curve of the number of daily infections will reach the maximum value and then converts to go down.

    Figure 10 shows that a reduction of the parameter $\alpha $ leads to a reduction in both the reproduction number ${\Re _0}$ and the number of daily infections. Figures 11 and 12 show that the parameters ${\sigma _2}\, {\rm{and}}\, \, r$ have significant effects on the number of daily infections, where a decrease in the value of each one of them leads to a reduction in the value of the number of daily infections and creates a peak point situation on its curve. We did not examine the parameters ${d_1}\, {\rm{and}}\, {d_2}$ where no one has a control to change the rates of death and that rates are out of our hands. Figure 11 represents that the peak of spreading COVID-19 in Saudi Arabia could be on February 8, 2021, if we could decrease the value of the parameter $\alpha $ to be in the following range $\alpha = \left( {1.0 - 3.0} \right) \times {10^{ - 10}}$, which makes the reproduction number ${\Re _0}$ very small and set in the interval $\left( {0.001 - 0.004} \right)$. Figure 12 represents that the peak of spreading COVID-19 in Saudi Arabia could be on December 25, 2020, if we could increase the value of the parameter ${\sigma _2} = 0.02$, which makes the reproduction number ${\Re _0} < 1$ and setting in the interval $\left( {0.213 - 0.638} \right)$. Figure 13 shows that the peak of spreading COVID-19 in Saudi Arabia could be on September 26, 2020, if we could increase the value of the parameter $r = 0.01$ and $\alpha = 1.0 \times {10^{ - 9}}$, which makes the reproduction number ${\Re _0} = 0.213$.

    Figure 10.  The number of daily infections for 400 days when the values of $\alpha $ decreased.
    Figure 11.  The number of daily infections for 400 days when the value of ${\sigma _2}$ increased.
    Figure 12.  The number of daily infections for 400 days when the value of $r$ increased.
    Figure 13.  The number of daily infections for 400 days when the values of all parameters $\alpha , {\sigma _2}, \, \, {\rm{and}}\, \, r$ changed.

    According to the results in Figures 1012, we can get the ideal situation of breakdown the spreading of COVID-19 in Saudi Arabia when we merge all the changes of the parameter at the same time to get the ideal case. So, we will calculate the number of daily infections based on the new values of the parameters, as in Table 3 as follows:

    Table 3.  The new values of parameters in SEIR which gives an ideal situation.
    Parameter Value Background
    $\Lambda $ 2300 Calculated
    ${\sigma _1}$ $0.0024$ Calculated
    ${\sigma _2}$ $2.0 \times {10^{ - 2}}$ Estimated
    $r$ $0.01$ Calculated
    ${d_1}$ $3.0 \times {10^{ - 5}}$ Calculated
    ${d_2}$ $2.7 \times {10^{ - 5}}$ Calculated

     | Show Table
    DownLoad: CSV

    Figure 13 shows the number of daily infections when we apply the values of the parameters, as in Table 3, which gives us the best situation to breakdown the spreading of the COVID-19 in Saudi Arabia in the next stage. The figure represents that the daily number of infections will go down faster when we change all the parameters as in Table 3 more than changing each parameter separately. Moreover, it is clear to see that the spreading will breakdown immediately after reaching those values of the parameters, and the breakdown of spreading COVID-19 could be on July 31, 2020. Thus, by going back to the definition of each parameter, we know now what we should do to breakdown the spreading of COVID-19 in Saudi Arabia. So, we can write the best protocol, which must the population in Saudi Arabia follow it to breakdown the spread of COVID-19 in Saudi Arabia and go back to their natural life.

    To get the ideal situation which can help us to the breakdown of spreading COVID-19 in Saudi Arabia, we must start implementing the following protocol and procedures (see Figure 14).

    Figure 14.  The flowchart of the ideal protocol based on proposed SEIR model.

    (1) They are decreasing the value of the transmission rate from the susceptible population to infected but not detected by testing the population to be $\alpha < 1.8 \times {10^{ - 9}}$.

    (2) They are increasing the value of the transmission rate from infected and detected by testing the population to the recovery zone to be ${\sigma _2} > 0.004$ by using a successful treatment and work with the principle of prevention is better than treatment.

    (3) They are increasing the value of the transmission rate population $r$ to be $r > 0.005$, which means we have to increase the number of tests which help us to determine the population who confirmed infection and sit them in a separate zone where they are sitting with other population will increase the diseases.

    This paper proposed a new statistical SEIR epidemic for the outbreak of new COVID-19 coronaviruses. This proposed pandemic model offers a new method for evaluating and handling the COVID-19 epidemic. The real data of spreading COVID-19 in Saudi Arabia has been used to verify the results of that proposed model. The results show that the proposed SEIR model is a successful model to analyze the spreading of epidemics like COVID-19 in Saudi Arabia. The ideal protocol consists some steps, and advices have been introduced in detail to help the Saudi Arabia population to speed the breakdown spreading of COVID-19. One of the main subjects in that protocol is prevention is better than treatment. The other essential issue which helps to breakdown the spread of COVID-19 is to stay away and be at home as you can and make the infected people in an isolated zone or secured area.

    Lastly, we need to increase the number of tests that confirm the infection and include effective and sufficient medication and vitamins, tonics, and supplements to protect non-infected individuals.

    This work was funded by Research and Development Grants Program for National Research Institutions and Centers (GRANTS), Target Research Program, Infectious Diseases Research Grant Program, King Abdulaziz City for Science and Technology (KACST), Kingdom of Saudi Arabia, [grant number (5-20-01-007-0002)]. The authors are very grateful and thank the Research and Development Grants Program for National Research Institutions and Centers (GRANTS), Target Research Program, Infectious Diseases Research Grant Program, King Abdulaziz City for Science and Technology (KACST), Kingdom of Saudi Arabia, to fund this project and this work.

    The Authors declare that this work has no conflict of interest.


    Acknowledgments



    The authors gratefully thank University of Malaya and the Ministry of Higher Education, Malaysia for the HIR-MOHE Research Grant F000002-21001 funding and Mohammad Azizur Rahman is grateful for the grant-in-aid provided by Jahangirnagar University and the University Grants Commission of Bangladesh.

    Conflict of interest



    The author reports no conflicts of interest and has received no payment in preparation of this manuscript.

    [1] Reiman EM (2014) Alzheimer's disease and other dementias: advances in 2013. Lancet Neurol 13: 3–5. doi: 10.1016/S1474-4422(13)70257-6
    [2] Liao L, Cheng D, Wang J, et al. (2004) Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279: 37061–37068. doi: 10.1074/jbc.M403672200
    [3] Wang Q, Wu J, Rowan MJ, et al. (2005) β‐amyloid inhibition of long‐term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 22: 2827–2832. doi: 10.1111/j.1460-9568.2005.04457.x
    [4] Lecanu L, Papadopoulos V (2013) Modeling Alzheimer's disease with non-transgenic rat models. Alzheimers Res Ther 5: 17.
    [5] Sparks DL, Scheff SW, Hunsaker JC, et al. (1994) Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126: 88–94. doi: 10.1006/exnr.1994.1044
    [6] Refolo LM, Malester B, LaFrancois J, et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321–331. doi: 10.1006/nbdi.2000.0304
    [7] Anstey KJ, Lipnicki DM, Low LF (2008) Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16: 343–354. doi: 10.1097/01.JGP.0000310778.20870.ae
    [8] Ansari MA, Scheff SW (2010) Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 69: 155–167. doi: 10.1097/NEN.0b013e3181cb5af4
    [9] McLellan ME, Kajdasz ST, Hyman BT, et al. (2003) In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci 23: 2212–2217. doi: 10.1523/JNEUROSCI.23-06-02212.2003
    [10] Li F, Calingasan NY, Yu F, et al. (2004) Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 89: 1308–1312. doi: 10.1111/j.1471-4159.2004.02455.x
    [11] Dumont M, Wille E, Stack C, et al. (2009) Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 23: 2459–2466. doi: 10.1096/fj.09-132928
    [12] Murakami K, Murata N, Noda Y, et al. (2011) SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 286: 44557–44568. doi: 10.1074/jbc.M111.279208
    [13] Dröge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82: 47–95. doi: 10.1152/physrev.00018.2001
    [14] Tramutola A, Lanzillotta C, Perluigi M, et al. (2017) Butterfield, Oxidative stress, protein modification and Alzheimer disease. Brain Res Bull 133: 88–99. doi: 10.1016/j.brainresbull.2016.06.005
    [15] Mamun AA, Hashimoto M, Katakura M, et al. (2014) neuroprotective effect of madecassoside evaluated using amyloid Β 1-42 -mediated in vitro and in vivo Alzheimer's disease models. Intl J Indigenous Med Plants 47: 1669–1682.
    [16] Olton DS, Samuelson RJ (1976) Remembrance of places passed: spatial memory in rats. J Exp Psychol Anim Behav Process 2: 97–116. doi: 10.1037/0097-7403.2.2.97
    [17] Jarrard LE, Okaichi H, Steward O, et al. (1984) On the role of hippocampal connections in the performance of place and cue tasks: comparisons with damage to hippocampus. Behav Neurosci 98: 946–954. doi: 10.1037/0735-7044.98.6.946
    [18] Shevchenko G, Sjödin MO, Malmström D, et al. (2010) Cloud-point extraction and delipidation of porcine brain proteins in combination with bottom-up mass spectrometry approaches for proteome analysis. J Proteome Res 9: 3903–3911. doi: 10.1021/pr100116k
    [19] Stepanichev MY, Zdobnova IM, Zarubenko II, et al. (2007) Studies of the effects of central administration of β-amyloid peptide (25–35): pathomorphological changes in the hippocampus and impairment of spatial memory. Neurosci Behav Physiol 36: 101–106.
    [20] Holscher C, Gengler S, Gault VA, et al. (2007) Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 561: 85–90. doi: 10.1016/j.ejphar.2007.01.040
    [21] Parihar MS, Brewer GJ (2007) Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 292: C8–C23. doi: 10.1152/ajpcell.00232.2006
    [22] Butterfield DA, Hardas SS, Lange ML (2010) Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration. J Alzheimers Dis 20: 369–393. doi: 10.3233/JAD-2010-1375
    [23] Minjarez B, Valero Rustarazo ML, Sanchez del Pino MM, et al. (2013) Identification of polypeptides in neurofibrillary tangles and total homogenates of brains with Alzheimer's disease by tandem mass spectrometry. J Alzheimers Dis 34: 239–262. doi: 10.3233/JAD-121480
    [24] Musunuri S, Wetterhall M, Ingelsson M, et al. (2014) Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry. J Proteome Res 13: 2056–2068. doi: 10.1021/pr401202d
    [25] Butterfield DA, Perluigi M, Reed T, et al. (2012) Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal 17: 1610–1655. doi: 10.1089/ars.2011.4109
    [26] Poon HF, Calabrese V, Calvani M, et al. (2006) Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by L-acetylcarnitine: insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid Redox Signal 8: 381–394. doi: 10.1089/ars.2006.8.381
    [27] Díez‐Vives C, Gay M, García‐Matas S, et al. (2009) Proteomic study of neuron and astrocyte cultures from senescence‐accelerated mouse SAMP8 reveals degenerative changes. J Neurochem 111: 945–955. doi: 10.1111/j.1471-4159.2009.06374.x
    [28] Blair LJ, Zhang B, Dickey CA (2013) Potential synergy between tau aggregation inhibitors and tau chaperone modulators. Alzheimers Res Ther 5: 41–50. doi: 10.1186/alzrt207
    [29] Yao J, Irwin RW, Zhao L, et al. (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. PNAS 106: 14670–14675. doi: 10.1073/pnas.0903563106
    [30] Cui Y, Huang M, He Y, et al. (2011) Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model. Am J Pathol 178: 1298–1308. doi: 10.1016/j.ajpath.2010.11.057
    [31] Keeney JTR, Swomley AM, Förster S, et al. (2013) Apolipoprotein A‐I: Insights from redox proteomics for its role in neurodegeneration. Proteomics Clin Appl 7: 109–122. doi: 10.1002/prca.201200087
    [32] Liu HC, Hu CJ, Chang JG, et al. (2006) Proteomic identification of lower apolipoprotein AI in Alzheimer's disease. Dement Geriatr Cogn Disord 21: 155–161. doi: 10.1159/000090676
    [33] Corder EH, Saunders AM, Strittmatter WJ, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921–923. doi: 10.1126/science.8346443
    [34] Sizova D, Charbaut E, Delalande F, et al. (2007) Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis. Neurobiol Aging 28: 357–370. doi: 10.1016/j.neurobiolaging.2006.01.011
    [35] Ellis RJ, Olichney JM, Thal LJ, et al. (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: The CERAD experience, part XV. Neurology 46: 1592–1596. doi: 10.1212/WNL.46.6.1592
    [36] Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287–303. doi: 10.1016/j.neuron.2009.06.026
    [37] Choi J, Gao J, Kim J, et al. (2015) The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis. Sci Transl Med 7: 314ra184.
    [38] Tosto G, Reitz C (2013) Genome-wide association studies in Alzheimer's disease: A review. Curr Neurol Neurosci Rep 13: 381. doi: 10.1007/s11910-013-0381-0
    [39] Yu JT, Tan L (2012) The role of clusterin in Alzheimer's disease: pathways, pathogenesis and therapy. Mol Neurobiol 45: 314–326. doi: 10.1007/s12035-012-8237-1
    [40] Hong I, Kang T, Yoo Y, et al. (2013) Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimer's disease pathology. J Alzheimers Dis 36: 321–334. doi: 10.3233/JAD-130311
    [41] Puglielli L, Konopka G, Pack-Chung E, et al. (2001) Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nat Cell Biol 3: 905–912. doi: 10.1038/ncb1001-905
    [42] Sjögren M, Mielke M, Gustafson D, et al. (2006) Cholesterol and Alzheimer's disease-is there a relation? Mech Ageing Dev 127: 138–147. doi: 10.1016/j.mad.2005.09.020
    [43] Cortes-Canteli M, Zamolodchikov D, Ahn HJ, et al. (2012) Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis 32: 599–608. doi: 10.3233/JAD-2012-120820
    [44] Ahn HJ, Zamolodchikov D, Cortes-Canteli M, et al. (2010) Alzheimer's disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A 107: 21812–21817. doi: 10.1073/pnas.1010373107
    [45] Li X, Buxbaum JN (2011) Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener 6: 79. doi: 10.1186/1750-1326-6-79
    [46] Flynn JM, Melov S (2013) SOD2 in mitochondrial dysfunction and neurodegeneration. Free Radic Biol Med 62: 4–12. doi: 10.1016/j.freeradbiomed.2013.05.027
    [47] De Leo ME, Borrello S, Passantino M, et al. (1998) Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci Lett 250: 173–176. doi: 10.1016/S0304-3940(98)00469-8
    [48] Manavalan A, Mishra M, Sze SK, et al. (2013) Brain-site-specific proteome changes induced by neuronal P60TRP expression. Neurosignals 21: 129–149. doi: 10.1159/000343672
    [49] Sun KH, Chang KH, Clawson S, et al. (2011) Glutathione‐S‐transferase P1 is a critical regulator of Cdk5 kinase activity. J Neurochem 118: 902–914. doi: 10.1111/j.1471-4159.2011.07343.x
    [50] Luo J, Wärmländer SKTS, Gräslund A, et al. (2014) Non-chaperone proteins can inhibit aggregation and cytotoxicity of Alzheimer amyloid β peptide. J Biol Chem 289: 27766–27775. doi: 10.1074/jbc.M114.574947
    [51] Habib KL, Lee TCM, Yang J (2010) Inhibitors of catalase-amyloid interactions protect cells from β-amyloid-induced oxidative stress and toxicity. J Biol Chem 285: 38933–38943. doi: 10.1074/jbc.M110.132860
    [52] Cocciolo A, Di Domenico F, Coccia R, et al. (2012) Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radic Biol Med 53: 1868–1876. doi: 10.1016/j.freeradbiomed.2012.08.596
    [53] Spagnuolo MS, Maresca B, La Marca V, et al. (2014) Haptoglobin interacts with apolipoprotein E and beta-amyloid and influences their crosstalk. ACS Chem Neurosci 5: 837–847. doi: 10.1021/cn500099f
    [54] Poynton AR, Hampton MB (2014) Peroxiredoxins as biomarkers of oxidative stress. Biochim Biophys Acta 1840: 906–912. doi: 10.1016/j.bbagen.2013.08.001
  • neurosci-06-04-299-s001.pdf
  • This article has been cited by:

    1. Manuel De la Sen, Santiago Alonso-Quesada, Asier Ibeas, On a Discrete SEIR Epidemic Model with Exposed Infectivity, Feedback Vaccination and Partial Delayed Re-Susceptibility, 2021, 9, 2227-7390, 520, 10.3390/math9050520
    2. Hongfan Lu, Yuting Ding, Silin Gong, Shishi Wang, Mathematical modeling and dynamic analysis of SIQR model with delay for pandemic COVID-19, 2021, 18, 1551-0018, 3197, 10.3934/mbe.2021159
    3. Hamdy Youssef, Najat Alghamdi, Magdy A. Ezzat, Alaa A. El-Bary, Ahmed M. Shawky, Study on the SEIQR model and applying the epidemiological rates of COVID-19 epidemic spread in Saudi Arabia, 2021, 6, 24680427, 678, 10.1016/j.idm.2021.04.005
    4. Manuel De la Sen, Santiago Alonso-Quesada, Asier Ibeas, Raul Nistal, On a Discrete SEIR Epidemic Model with Two-Doses Delayed Feedback Vaccination Control on the Susceptible, 2021, 9, 2076-393X, 398, 10.3390/vaccines9040398
    5. Xinyu Liu, Zimeng Lv, Yuting Ding, Mathematical modeling and stability analysis of the time-delayed $ SAIM $ model for COVID-19 vaccination and media coverage, 2022, 19, 1551-0018, 6296, 10.3934/mbe.2022294
    6. Muhammad Abdurrahman Rois, Cicik Alfiniyah, Chidozie W. Chukwu, Dynamic analysis and optimal control of COVID-19 with comorbidity: A modeling study of Indonesia, 2023, 8, 2297-4687, 10.3389/fams.2022.1096141
    7. Shabana Bibi, Muhammad Saad Khan, Sherif A. El-Kafrawy, Thamir A. Alandijany, Mai M. El-Daly, Qudsia Yousafi, Dua Fatima, Arwa A. Faizo, Leena H. Bajrai, Esam I. Azhar, Virtual screening and molecular dynamics simulation analysis of Forsythoside A as a plant-derived inhibitor of SARS-CoV-2 3CLpro, 2022, 30, 13190164, 979, 10.1016/j.jsps.2022.05.003
    8. Mengying Wang, Cuixia Lee, Wei Wang, Yingyun Yang, Cheng Yang, Yi-Zhang Jiang, Early Warning of Infectious Diseases in Hospitals Based on Multi-Self-Regression Deep Neural Network, 2022, 2022, 2040-2309, 1, 10.1155/2022/8990907
    9. R. Prem Kumar, P.K. Santra, G.S. Mahapatra, Global stability and analysing the sensitivity of parameters of a multiple-susceptible population model of SARS-CoV-2 emphasising vaccination drive, 2023, 203, 03784754, 741, 10.1016/j.matcom.2022.07.012
    10. Ali Yousef, Fatma Bozkurt, Thabet Abdeljawad, Emad Emreizeeq, A mathematical model of COVID-19 and the multi fears of the community during the epidemiological stage, 2023, 419, 03770427, 114624, 10.1016/j.cam.2022.114624
    11. Jiaji Pan, Zhongxiang Chen, Yixuan He, Tongliang Liu, Xi Cheng, Jun Xiao, Hao Feng, Why Controlling the Asymptomatic Infection Is Important: A Modelling Study with Stability and Sensitivity Analysis, 2022, 6, 2504-3110, 197, 10.3390/fractalfract6040197
    12. Othman A.M. Omar, Yousef Alnafisah, Reda A. Elbarkouky, Hamdy M. Ahmed, COVID-19 deterministic and stochastic modelling with optimized daily vaccinations in Saudi Arabia, 2021, 28, 22113797, 104629, 10.1016/j.rinp.2021.104629
    13. Moirangthem Bidyaluxmi Devi, Arpita Devi, Praveen Kumar Gupta, Dharmendra Tripathi, Response of vaccination on community transmission of COVID-19: a dynamical approach, 2022, 231, 1951-6355, 3749, 10.1140/epjs/s11734-022-00652-0
    14. Abdullah Ahmadini, Ahmed Msmali, Zico Mutum, Yashpal Singh Raghav, Anibal Coronel, The Mathematical Modeling Approach for the Wastewater Treatment Process in Saudi Arabia during COVID-19 Pandemic, 2022, 2022, 1607-887X, 1, 10.1155/2022/1061179
    15. Zhaobin Xu, Dongqing Wei, Qiangcheng Zeng, Hongmei Zhang, Yinghui Sun, Jacques Demongeot, More or less deadly? A mathematical model that predicts SARS-CoV-2 evolutionary direction, 2023, 153, 00104825, 106510, 10.1016/j.compbiomed.2022.106510
    16. Ali AlArjani, Md Taufiq Nasseef, Sanaa M. Kamal, B. V. Subba Rao, Mufti Mahmud, Md Sharif Uddin, Application of Mathematical Modeling in Prediction of COVID-19 Transmission Dynamics, 2022, 47, 2193-567X, 10163, 10.1007/s13369-021-06419-4
    17. Ziren Chen, Lin Feng, Harold A. Lay, Khaled Furati, Abdul Khaliq, SEIR model with unreported infected population and dynamic parameters for the spread of COVID-19, 2022, 198, 03784754, 31, 10.1016/j.matcom.2022.02.025
    18. Abdullah A. Al-Shammari, Hamad Ali, Barrak Alahmad, Faisal H. Al-Refaei, Salman Al-Sabah, Mohammad H. Jamal, Abdullah Alshukry, Qais Al-Duwairi, Fahd Al-Mulla, The Impact of Strict Public Health Measures on COVID-19 Transmission in Developing Countries: The Case of Kuwait, 2021, 9, 2296-2565, 10.3389/fpubh.2021.757419
    19. Haile Habenom, Mulualem Aychluh, D.L. Suthar, Qasem Al-Mdallal, S.D. Purohit, Modeling and analysis on the transmission of covid-19 Pandemic in Ethiopia, 2022, 61, 11100168, 5323, 10.1016/j.aej.2021.10.054
    20. Kamal Shah, Thabet Abdeljawad, Rahim Ud Din, To study the transmission dynamic of SARS-CoV-2 using nonlinear saturated incidence rate, 2022, 604, 03784371, 127915, 10.1016/j.physa.2022.127915
    21. Raffaele D’Ambrosio, Patricia Díaz de Alba, Giuseppe Giordano, Beatrice Paternoster, 2022, Chapter 7, 978-3-031-10521-0, 90, 10.1007/978-3-031-10522-7_7
    22. Fahad M. Alswaidi, Abdullah M. Assiri, Haya H. Alhaqbani, Mohrah M. Alalawi, Characteristics and outcome of COVID-19 cases in Saudi Arabia: Review of six-months of data (March–August 2020), 2021, 29, 13190164, 682, 10.1016/j.jsps.2021.04.030
    23. Sadiqah Al Marzooq, COVID-19 OVERVIEW IN SAUDI ARABIA USING THE SIRV MODEL, 2023, 11, 2350-0530, 10.29121/granthaalayah.v11.i3.2023.5079
    24. Lijuan Niu, Qiaoling Chen, Zhidong Teng, Ramziya Rifhat, Ge Zhang, Stationary distribution and probability density function of a stochastic COVID-19 infections model with general incidence, 2024, 361, 00160032, 106963, 10.1016/j.jfranklin.2024.106963
    25. Faten S. Alamri, Edward L. Boone, Ryad Ghanam, Fahad Alswaidi, Monitoring COVID-19 pandemic in Saudi Arabia using SEIRD model parameters with MEWMA, 2023, 16, 18760341, 2038, 10.1016/j.jiph.2023.09.009
    26. Jianlan Zhou, Guozhong Huang, Shenyuan Gao, Zhijin Chen, Xuehong Gao, Study on the influencing factors of piecewise multi-strain crossover epidemic spread under data contamination, 2023, 4, 26664496, 305, 10.1016/j.jnlssr.2023.07.002
    27. Yaroslav Vyklyuk, Denys Nevinskyi, Kateryna Hazdiuk, Continuous-discrete GeoSEIR(D) model for modelling and analysis of geo spread COVID-19, 2024, 10, 26665212, 100155, 10.1016/j.ibmed.2024.100155
    28. Mohamad Tafrikan, Yolanda Norasia, Aly Syafrudin, Muhammad Abdurrahman Rois, 2024, 3104, 0094-243X, 020009, 10.1063/5.0194546
    29. Poosan Moopanar Muthu, Anagandula Praveen Kumar, Optimal control and bifurcation analysis of SEIHR model for COVID-19 with vaccination strategies and mask efficiency, 2024, 12, 2544-7297, 10.1515/cmb-2023-0113
    30. Nafe Moradkhani, Frederick Benaben, Benoit Montreuil, Matthieu Lauras, Thibaut Cerabona, Clara Le Duff, Louis Faugere, Julien Jeany, A force-inspired paradigm for performance-based decision support—Physics of Decision application in nonlinear dynamical systems, 2024, 41, 2452414X, 100656, 10.1016/j.jii.2024.100656
    31. Amr Elsonbaty, Waleed Adel, A. Aldurayhim, A. El-Mesady, Mathematical modeling and analysis of a novel monkeypox virus spread integrating imperfect vaccination and nonlinear incidence rates, 2024, 15, 20904479, 102451, 10.1016/j.asej.2023.102451
    32. Muhammad Abdurrahman Rois, Cicik Alfiniyah, Santi Martini, Dipo Aldila, Farai Nyabadza, Modeling and optimal control of COVID-19 with comorbidity and three-dose vaccination in Indonesia, 2024, 6, 25889338, 181, 10.1016/j.jobb.2024.06.004
    33. Shui-Lin Peng, Hong-Jue Wang, Hao Peng, Xiang-Bin Zhu, Xiang Li, Jianmin Han, Dandan Zhao, Zhao-Long Hu, NLSI: An innovative method to locate epidemic sources on the SEIR propagation model, 2023, 33, 1054-1500, 10.1063/5.0152859
    34. Yubo Fan, Lixin Yan, Cheng Zhang, Yating Chen, Danjie Wu, 2023, Predicting Material Demand During Sudden Health Emergencies Based on Enhanced SEIR-D Model, 9798400708138, 1358, 10.1145/3644116.3644361
    35. Sanad Al-Khawaja, Omar S. Asfour, The impact of COVID-19 on the importance and use of public parks in Saudi Arabia, 2024, 15, 20904479, 102286, 10.1016/j.asej.2023.102286
    36. Olena Kiseleva, Sergiy Yakovlev, Dmytro Chumachenko, Oleksandr Kuzenkov, Exploring Bifurcation in the Compartmental Mathematical Model of COVID-19 Transmission, 2024, 12, 2079-3197, 186, 10.3390/computation12090186
    37. Bolun Chen, Shuai Han, Xiaoluan Liu, Zhe Li, Ting Chen, Min Ji, Prediction of an epidemic spread based on the adaptive genetic algorithm, 2023, 11, 2296-424X, 10.3389/fphy.2023.1195087
    38. Zenebe Shiferaw Kifle, Legesse Lemecha Obsu, Mathematical modeling and analysis of COVID-19 and TB co-dynamics, 2023, 9, 24058440, e18726, 10.1016/j.heliyon.2023.e18726
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5126) PDF downloads(550) Cited by(6)

Figures and Tables

Figures(5)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog